Prevention of sudden coronary death by chronic antiarrhythmic therapy.
D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001073:Aprindine / Q000627:therapeutic use; D001949:Bretylium Compounds / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003645:Death, Sudden; D004206:Disopyramide / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D008801:Mexiletine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010672:Phenytoin / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000517:prevention & control*
D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D008801:Mexiletine; D001073:Aprindine; D010672:Phenytoin; D004206:Disopyramide; D011802:Quinidine; D011342:Procainamide; D000638:Amiodarone